Clinical and biomarker results from a phase II trial of combined cabozantinib and durvalumab in patients with chemotherapy-refractory colorectal cancer (CRC): CAMILLA CRC cohort.

Nat Commun · 2024 · PMC10879200 · PMID 38378868

Europe PMC DOI

hedged sentence

0.0500

closest p · 1.0× alpha

0.0500

boldest claim

The sentences

marginally significantp = 0.05actually significant

Cell deconvolution analysis showed significant increase in the abundance of fibroblasts in the TEC of responders with marginally significant increase in the fibroblasts in the SC ( p = 0.05).

also in 26,082 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.